Health and Healthcare
The FDA Strikes Again at Calithera Biosciences
Published:
Last Updated:
The U.S. Food and Drug Administration (FDA) has been busy this week, especially Wednesday, issuing multiple approvals to the likes of Rigel Pharmaceuticals and Teligent. Now Calithera Biosciences Inc. (NASDAQ: CALA) is joining the ranks, but in this case the firm is receiving a Fast Track designation for its kidney cancer treatment.
The FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs and biologics to treat serious or life threatening conditions and to fill an unmet medical needs.
Specifically, the FDA granted Fast Track designation to CB-839 in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma who have received one or two prior lines of therapy, including at least one vascular endothelial growth factor tyrosine kinase inhibitor or the combination of nivolumab and ipilimumab.
CB-839 is being evaluated in the CANTATA trial, which is a randomized double-blind clinical study of cabozantinib in combination with CB-839 or placebo in 298 patients with clear cell renal cell carcinoma. The primary endpoint is progression free survival and the global study is open for enrollment.
Susan Molineaux, Ph.D., president and CEO of Calithera, added:
Despite a number of new therapies for the treatment of renal cell carcinoma, there remains a significant unmet need among advanced patients who have received prior treatment. We are pleased that CB-839 has been granted Fast Track designation, demonstrating the FDA’s commitment to facilitate the development and expedite the review of our glutaminase inhibitor as an important new therapy for patients with advanced or metastatic renal cell carcinoma who have failed prior systemic therapy.
Excluding Wednesday’s move, Calithera had underperformed the broad markets with its stock down 42.5% in the past year. In just 2018 alone, the stock was down 24%.
Shares of Calithera were last seen up about 4% at $6.59, with a consensus analyst price target of $14.25 and a 52-week range of $5.35 to $20.05.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
